Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 4329 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

J&J gets Euro OK to expand Velcade label

Velcade (bortezomib) for injection is indicated as monotherapy for use in patients who have received at least one prior therapy and who have already undergone or are unsuitable

Forest’s Lexapro patent trial delayed

The US District Court has rescheduled opening arguments from May 9, 2005 to December 5, 2005 for the trial, related to patent litigation regarding the selective serotonin reuptake

Migenix cleared to start phase I/II neuro study

MX-4509 is an orally-administered drug candidate being developed for the treatment of neurodegenerative diseases. It was well tolerated in a phase I clinical trial and has demonstrated neuroprotective